Product Categories
Contact Us
Wuhan Dahua Weiye Pharmaceutical Chemical Co.,Ltd
Add: Building 4 ,Room 410,No.17 ,GUTIAN Road, Wuhan City, Hubei Province
Tel: +8618086445119
Fax: +86-27-83322098
Cell:+8618086445119
Emaill: dahuasales02@whdhwy.com
dahuasales03@whdhwy.com dh.jason@whdhwy.com

Degarelix Acetate

Degarelix Acetate

Quick Details Description Digaric, a gonadotropin hormone-releasing hormone receptor blocker, has been approved in the United States and Europe for advanced (hormone-dependent) prostate cancer treatment, and in Japan for prostate cancer treatment. A New Zealand study found that digaricol was no...

Products Specifications:

Quick Details

Product Name

Degarelix acetate

CAS

214766-78-6

EINECS

1312995-182-4

Molecular Formula

C82H103ClN18O16

Molecular Weight

1632.28

Appearance

White powder

Application

For advanced prostate cancer treatment

Purity

99%


Description


Digaric, a gonadotropin hormone-releasing hormone receptor blocker, has been approved in the United States and Europe for advanced (hormone-dependent) prostate cancer treatment, and in Japan for prostate cancer treatment.

A New Zealand study found that digaricol was no less effective in suppressing testosterone at a castration level (i.e., less than 0.5 ng/mL) than liangpraline (7.5mg per month intramuscular injection) in prostate cancer patients who had been treated with endocrine therapy (excluding hormone neoadjuvant therapy). The paper was published online in the journal Drugs in April 2014.

In this study, compared with liangpraline, digaricol had a rapid inhibition of testosterone and a rapid increase of various prostate-specific antigen (PSA) levels. Also, no testosterone surge or slight increase occurred in patients treated with digaric.

Testosterone inhibition and PSA levels were maintained during the 12-month study period and could last for up to five years (extended study duration of the main trial) (this extended study included patients who had switched from leprodrine to digaricol).

In general, digaric is well tolerated and most adverse events are mild to moderate. The most common adverse events are injection site reactions and some events that reflect the expected effect of testosterone inhibition (e.g., hot flashes and weight gain).

Therefore, digaric is an effective choice for the treatment of prostate cancer patients with endocrine therapy.

图片1

Hot Tags: degarelix acetate, China, manufacturers, factory, bulk, buy discount, in stock, free sample